Relatively recent IPO resTORbio (TORC +3.6%) reports that it has completed dosing in a Phase 2b clinical trial assessing lead candidate RTB101, as monotherapy and in combination with Novartis' AFINITOR (everolimus), in reducing the incidence of respiratory tract infections in the elderly.
The primary endpoint of the 652-subject study is the proportion of subjects with one or more respiratory tract infections through week 16. Topline data should be available next quarter.
Previously: IPO approaches for resTORbio (Jan. 2)
Subscribe for full text news in your inbox